|
|
 |
|
|
|
|
|
Latini R, Masson S, Pirelli S, Barlera S, Pulitano G, Carbonieri E, Gulizia M, Vago T, Favero C, Zdunek D, Struck J, Staszewsky L, Maggioni AP, Franzosi MG, Disertori M; on the behalf of the GISSI-AF Investigators. | Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial.
J Intern Med 2011. 269 : 160 - 171 |
Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, Cioffi G, Sinagra G, Mazzone C, Bertocchi F, Vago T, Peri G, Cuccovillo I, Masuda N, Barlera S, Mantovani A, Maggioni AP, Franzosi MG, Disertori M, Latini R; on behalf of the GISSI-AF investigators. | Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial.
Heart 2010. doi:10.1136/hrt.2009.191460 |
Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, Cioffi G, Sinagra G, Mazzone C, Bertocchi F, Vago T, Peri G, Cuccovillo I, Masuda N, Barlera S, Mantovani A, Maggioni A P, Franzosi M G, Disertori M, Latini R, GISSI-AF Investigators | Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial
Heart 2010. 96 : 1909 - 1914 |
GISSI-AF Investigators | Valsartan for prevention of recurrent atrial fibrillation.
New Engl J Med 2009. 360(16) : 1606 - 1617 |
Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G, on behalf of GISSI-AF Investigators | Rationale and design of the GISSI-atrial fibrillation trial: randomized, prospective, multicenter study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
J Cardiovasc Med 2006. 7 : 29 - 38 | |
|
|
|
|
|
| |
|
